Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: Cefepime for Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia. US FDA label
Kidney dosing: Cefepime (single-agent)Show full dosing details
- CrCl ≥60 mL/min
- CrCl >60: usual dose (label: 500 mg to 2 g every 8 to 12 hours by indication). CrCl of exactly 60: use the 30–60 row.
- CrCl 30–59 mL/min
- CrCl 30–60, by usual regimen: 500 mg q12h → 500 mg q24h; 1 g q12h → 1 g q24h; 2 g q12h → 2 g q24h; 2 g q8h → 2 g q12h. First dose as for normal function (label Table 2).
- CrCl 15–29 mL/min
- CrCl 11–29, by usual regimen: 500 mg q12h → 500 mg q24h; 1 g q12h → 500 mg q24h; 2 g q12h → 1 g q24h; 2 g q8h → 2 g q24h (label Table 2).
- CrCl <15 mL/min (not on dialysis)
- CrCl 11–14: as the 11–29 row. CrCl below 11, by usual regimen: 250 mg, 250 mg, 500 mg or 1 g every 24 hours respectively (label Table 2).
- Hemodialysis (intermittent)
- 1 g on day 1, then 500 mg every 24 hours; for the 2 g every 8 hours regimen (febrile neutropenia) 1 g every 24 hours; give at the same time each day and after hemodialysis on dialysis days (label). A 3-hour session removes about 68% of the drug in the body. Literature option (not label): thrice-weekly after each session, 2 g, 2 g and 2 g (1/1/1.5 g and 1.5/1.5/2 g reported in limited data) (Tsai 2025). Troughs of 22 mg/L or more have been associated with neurotoxicity; stop if encephalopathy or myoclonus appears. These regimens are not weight-adjusted and come mostly from small pharmacokinetic studies; confirm the actual last and next session before each dose. See the site guide Antibiotic Stewardship in Hemodialysis (/guides/antibiotic-stewardship-dialysis.html).
- Peritoneal dialysis
- CAPD: the usual dose every 48 hours (500 mg, 1 g, 2 g or 2 g by regimen) (label Table 2). For PD-associated peritonitis (ISPD 2022): intraperitoneal intermittent 1,000 mg daily; continuous loading dose 500 mg/L, then 125 mg/L in each exchange. Continuous cephalosporin doses may need about 25% more in patients with significant residual kidney function (ISPD 2022).
- CRRT
- Not in label. Li 2020 (Table 3): CVVH ultrafiltration 1,000 mL/h or less, 1 g every 8 hours; 1,500 mL/h or more, 2 g every 8 hours or 1 g every 6 hours; 30 mL/kg/h, 2 g every 8 hours as extended infusion. CVVHD dialysate 20–25 mL/kg/h, load 2 g, then 1.5–1.75 g every 8 hours. CVVHDF combined flow 1,000 mL/h or less, 1 g every 8 hours; 1,500 mL/h or more, 2 g every 8 hours or 1 g every 6 hours.
- Dialyzable? Yes: about 68% removed during a 3-hour hemodialysis (label). For overdose the label advises hemodialysis, not peritoneal dialysis. Protein binding about 20%.
- Monitoring CrCl for dose; neurotoxicity (encephalopathy, myoclonus, seizures, nonconvulsive status epilepticus), mainly with unadjusted doses in kidney impairment; stop cefepime if it occurs (label 5.2). Kidney function with aminoglycosides or loop diuretics.
From the Cefepime monograph (renalcarematters.com, reviewed).
- tazobactam no separate page
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- Powder for injection: 1 g/125 mg, 500 mg/62.5 mg
Registered products in the Philippines
2 products registered with the Food and Drug Administration (FDA) Philippines list Cefepime + Tazobactam as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
BlifetazCefepime (as hydrochloride) + Tazobactam (as sodium) | 500 mg/ 62.5 mg Powder for Injection (IM/IV)USP Type III clear glass vial x 10 mL with grey butyl rubber stopper, aluminum seal and green flip-off cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Afree Pharmaceutical Distribution CorpImporter: Afree Pharmaceutical Distribution Corp. | DRP-14510 | Sep 15, 2028 | |
SaptazCefepime (as hydrochloride) + Tazobactam (as sodium) | 1 g/125 mg Powder for Injection (IM/IV)20 mL Type I Clear Colorless Glass Vial + 10 mL Type I Clear Colorless Ampoule (Diluent) in a Plastic Tray per Box | Rx | Makcur Laboratories Ltd.India | Bell-Kenz Pharma Inc.Importer: SRS Life Sciences Inc. | DR-XY44446 | Feb 9, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .
